Polaryx Therapeutics (PLYX) Retained Earnings (2024 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly Retained Earnings of $104.7 million for Q1 2026, up 205.05% quarter-over-quarter from -$99.6 million in Q4 2025.
Polaryx Therapeutics (PLYX) Retained Earnings (2024 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Retained Earnings for 3 consecutive years, with $104.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings changed N/A year-over-year to $104.7 million; the TTM figure through Mar 2026 stood at $104.7 million (changed N/A YoY), while the FY2025 annual figure was -$99.6 million, down 204.49% from the prior year.
- Retained Earnings grew to $104.7 million in Q1 2026 per PLYX's latest filing, from -$99.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $104.7 million in Q1 2026 and bottomed at -$99.6 million in Q4 2025.
- Historically, Retained Earnings has averaged $33.5 million across 3 years, with a median of $95.4 million in 2024.
- On a YoY basis, Retained Earnings climbed as much as 204.49% in 2025 and fell as far as 204.49% in 2025.
- Polaryx Therapeutics' Retained Earnings stood at $95.4 million in 2024, then plunged by 204.49% to -$99.6 million in 2025, then surged by 205.05% to $104.7 million in 2026.
- Business Quant data shows PLYX's Retained Earnings at $104.7 million in Q1 2026, -$99.6 million in Q4 2025, and $95.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Polaryx Therapeutics | 99.45 Mn | 87.91 Mn | - | 114.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114.49 Mn |
| Mar 31, 2026 | 104.66 Mn |
| Dec 31, 2025 | -99.64 Mn |
| Dec 31, 2024 | 95.36 Mn |